Edition:
United States

Shanghai Pharmaceuticals Holding Co Ltd (601607.SS)

601607.SS on Shanghai Stock Exchange

24.12CNY
18 Dec 2017
Change (% chg)

¥0.07 (+0.29%)
Prev Close
¥24.05
Open
¥23.85
Day's High
¥24.14
Day's Low
¥23.68
Volume
6,467,362
Avg. Vol
14,243,983
52-wk High
¥29.25
52-wk Low
¥19.01

Chart for

About

Shanghai Pharmaceuticals Holding Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceuticals. The Company's businesses include the research and registration, production, sales, distribution and retailing of pharmaceutical products, among others. Its products are applied in cardiovascula... (more)

Overall

Beta: 0.97
Market Cap(Mil.): ¥59,345.07
Shares Outstanding(Mil.): 2,688.91
Dividend: 0.36
Yield (%): 1.50

Financials

  Industry Sector
P/E (TTM): -- 22.70 16.04
EPS (TTM): -- -- --
ROI: -- 12.02 34.69
ROE: -- 13.56 15.46

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 11 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its Shanghai-based unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 05 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

Dec 03 2017

BRIEF-Shanghai Pharmaceuticals Holding unit to take out loan of $100 mln

* Says co's Hong Kong-based wholly owned unit will take out loan of $100 million (about 664 million yuan) form co's controlling shareholder, with term of 180 days

Nov 15 2017

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 million

Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.

Nov 15 2017

UPDATE 3-Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

* Cardinal Health put business up for sale due to rule changes

Nov 15 2017

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

Nov 15 State-owned Shanghai Pharmaceuticals Holding Co has agreed to acquire Cardinal Health Inc's China business, one of the nation's largest drug distributors, for $557 million.

Nov 14 2017

BRIEF-Cardinal Health to sell its china business to Shanghai Pharma for $1.2 bln‍​

* Cardinal health signs definitive agreement to sell its china business to Shanghai Pharma

Nov 14 2017

BRIEF-Shanghai Pharmaceuticals' unit‍ signs deal to acquire Cardinal in Malaysia

* Says its unit‍ Century Global signs deal to acquire Cardinal Malaysia for about $557 million

Nov 14 2017

BRIEF-Shanghai Pharmaceuticals Holding Co ‍says unit to buy Cardinal Malaysia for US$557 mln

* ‍Century Global to buy Cardinal Malaysia from Cardinal Cayman for US$557 million Source text for Eikon: Further company coverage:

Nov 14 2017

Earnings vs. Estimates